Skip to main content
Clinical Trials/NCT01884168
NCT01884168
Completed
Not Applicable

Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy

Capital Medical University1 site in 1 country30 target enrollmentMarch 2013
ConditionsMalignant Tumor

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malignant Tumor
Sponsor
Capital Medical University
Enrollment
30
Locations
1
Primary Endpoint
Immunotherapy response
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor presenting malignant cavity effusion after DC-CIK immunotherapy.

Detailed Description

1. The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally. 2. Malignant cavity effusion from cancer patients is obtained through puncture and is centrifugalized to get supernatant fluid and enrich cancer cells before and after the therapy. 3. The enriched cancer cells which are flash frozen, as well as the supernatant, are stored at -80°C until processing. 4. The T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion. 5. Statistical analysis is performed using unsupervised hierarchical cluster.

Registry
clinicaltrials.gov
Start Date
March 2013
End Date
May 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Capital Medical University
Responsible Party
Principal Investigator
Principal Investigator

Jun Ren MD, PhD

Director

Capital Medical University

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed with malignant tumor and malignant cavity effusion.
  • An Eastern Cooperative Oncology Group(ECOG)performance status of 0-
  • Normal cardiac, hepatic, renal and bone marrow functions.
  • Life expectancy \>3 months.
  • Not receive other anti-tumor treatment.
  • Not receive chemotherapy in pleural and abdominal cavity.

Exclusion Criteria

  • Previous history of other malignancies.
  • Serious or uncontrolled concurrent medical illness.

Outcomes

Primary Outcomes

Immunotherapy response

Time Frame: 1 month

T-Cell Receptor and B-Cell Receptor gene expression profiling and the change of cytokines, lymphocytes subpopulation before and after DC-CIK infusion

Study Sites (1)

Loading locations...

Similar Trials